No AI summary available for this article.
Why It Matters
Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment.
Provenance
Discovered via ArXiv and published by ArXiv.
Key Claims
Original description
Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organizat...
Discovered via ArXiv
Research papers and preprints from arXiv.
Publisher: arxiv.org
ID: http://arxiv.org/abs/2609.21859v1 · Indexed about 8 hours ago